Sunshine Biopharma (NASDAQ:SBFM) Rating Increased to Hold at Zacks Research

Sunshine Biopharma (NASDAQ:SBFM) was upgraded by analysts at Zacks Research to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

Separately, Weiss Ratings restated a “sell (e+)” rating on shares of Sunshine Biopharma in a report on Tuesday, April 21st. One equities research analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $7.00.

Sunshine Biopharma Price Performance

Shares of NASDAQ:SBFM opened at $0.32 on Wednesday. Sunshine Biopharma has a 1 year low of $0.28 and a 1 year high of $2.43. The company has a market cap of $1.59 million, a PE ratio of -0.25 and a beta of 1.37. The stock’s 50-day moving average is $0.89 and its 200 day moving average is $1.15.

Sunshine Biopharma shares are going to reverse split on the morning of Monday, June 1st. The 1-10 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the market closes on Sunday, May 31st.

Sunshine Biopharma (NASDAQ:SBFM) last announced its quarterly earnings results on Wednesday, May 13th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.09). Sunshine Biopharma had a negative net margin of 18.45% and a negative return on equity of 27.75%. The business had revenue of $8.09 million for the quarter, compared to analysts’ expectations of $9.20 million. Analysts expect that Sunshine Biopharma will post -0.63 EPS for the current fiscal year.

Institutional Trading of Sunshine Biopharma

A number of hedge funds have recently modified their holdings of SBFM. Virtu Financial LLC bought a new stake in shares of Sunshine Biopharma during the 4th quarter valued at $29,000. Two Sigma Investments LP bought a new stake in shares of Sunshine Biopharma during the 3rd quarter valued at $32,000. Finally, Citadel Advisors LLC boosted its holdings in shares of Sunshine Biopharma by 23.1% during the 3rd quarter. Citadel Advisors LLC now owns 78,087 shares of the company’s stock valued at $116,000 after buying an additional 14,656 shares in the last quarter. Institutional investors own 41.98% of the company’s stock.

Sunshine Biopharma Company Profile

Sunshine Biopharma, Inc is a biotechnology company focused on the research, development and commercialization of novel drug candidates primarily for oncology. The company specializes in small-molecule therapeutics designed to overcome multidrug resistance and to target hard-to-treat cancers. Its preclinical pipeline emphasizes compounds that intercalate DNA and inhibit topoisomerase II, with the goal of advancing candidates into clinical trials for various solid tumors.

Among its lead programs, Sunshine Biopharma is advancing anthracycline-based compounds, including Bisantrene, which has demonstrated activity against breast and prostate cancer cell lines, and Adva-27a, a novel analog being evaluated for glioblastoma multiforme and other drug-resistant malignancies.